Terry Kohler was named Chief Financial Officer of Adma Biologics, Inc., succeeding Brad Tade, effective February 26, 2026. As of November 14, 2026, Adma Biologics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 25, 2026, naming 1 appointment and 1 departure (Form 8-K, February 25, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Adma Biologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Adma Biologics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-25. It names 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Adma Biologics, Inc. files it.
Also on the record for Adma Biologics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 6.1% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 7.4% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.08% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Invesco Ltd. | 5% of the class | 5%+ stakes | Source |
| August 11, 2025 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.1% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 8.94% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Adma Biologics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Adma Biologics, Inc. and the records around it.
Adma Biologics, Inc. elsewhere on the record
Companies that share a holder
- Invesco Ltd. also filed stake reports on 93 other companies: Alignment Healthcare Inc (Nov 2026), ArcBest Corp (Nov 2026), Canaan Inc (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 378 other companies: 4D MOLECULAR THERAPEUTICS INC (Nov 2026), ACADIA PHARMACEUTICALS INC (Nov 2026), ALBEMARLE CORP (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Adma Biologics, Inc.
Get an email when Adma Biologics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Adma Biologics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Adma Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adma Biologics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-25 | Out | Chief Financial Officer | 8-K, 2026-02-25 | ||
| 2026-02-25 | In | Chief Financial Officer | 2026-02-26 | 8-K, 2026-02-25 |
Why did they leave? What the filings say
Adma Biologics, Inc.'s filings state no reason for the departures below. Where a filing gives none, it says so here; nothing is inferred.
- Brad Tade, Chief Financial Officer (filed 2026-02-25): the filing states no reason.
Who leads Adma Biologics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Terry Kohler, appointed, effective 2026-02-26 (filed 2026-02-25).
New leaders reset buying decisions — get the Full Report on Adma Biologics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Adma Biologics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Adma Biologics, Inc.Every change, in the filing's words
Departing: Brad Tade, Chief Financial Officer
Tade Retirement; CFO Transition On February 20, 2026, Brad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K").
Appointed: Terry Kohler, Chief Financial Officer, effective 2026-02-26
Kohler Promotion On February 25, 2026, the Board of Directors of the Company (the "Board") promoted Mr. Kohler to Chief Financial Officer and Treasurer of the Company, effective February 26, 2026.
- Mr. Tade will transition from these positions to a consulting role with the Company, and will be immediately succeeded by Terry Kohler, currently the Company's Executive Financial Advisor (the "CFO Transition").
- In connection with the CFO Transition, on February 25, 2026, the Company and Mr. Tade entered into a Separation Agreement and Release (the "Separation Agreement") and a Consulting Services Agreement (the "Consulting Agreement" and, together with the Separation Agreement, the "Tade Agreements") pursuant to which, among other things, Mr. Tade will serve as a consultant to the Company.
- In accordance with the terms of the Consulting Agreement, Mr. Tade will provide financial and investor relations-related consulting and transition services to the Company as reasonably requested by the President and Chief Executive Officer and the General Counsel.
- Unless terminated earlier by either party on seven (7) days' written notice, the Consulting Agreement will automatically terminate on July 31, 2026 (the "Term").
- Pursuant to the Tade Agreements, commencing in March 2026, through the end of the Term, the Company will pay Mr. Tade a monthly gross amount of $41,666.67.
- Mr. Tade will also remain eligible to participate in the Company's equity incentive plans with respect to the continued vesting of his unvested and outstanding equity awards through the end of the Term.
Tools for this story
Each opens in a new tab, filled in for Adma Biologics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
